These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 29371221)
1. Bringing Vioxx back to market. Ross JS; Krumholz HM BMJ; 2018 Jan; 360():k242. PubMed ID: 29371221 [No Abstract] [Full Text] [Related]
2. The Vioxx® legacy: Enduring lessons from the not so distant past. McIntyre WF; Evans G Cardiol J; 2014; 21(2):203-5. PubMed ID: 24752949 [No Abstract] [Full Text] [Related]
3. Bringing the FDA's Information to Market. Woloshin S; Schwartz LM Arch Intern Med; 2009 Nov; 169(21):1985-7. PubMed ID: 19933960 [No Abstract] [Full Text] [Related]
4. Editorial overview: from Vioxx to Luckenbach: drug discovery at a crossroads. Williams M Curr Opin Investig Drugs; 2005 Jan; 6(1):17-20. PubMed ID: 15675599 [No Abstract] [Full Text] [Related]
5. Unnecessary withdrawal of Vioxx. Adams D N Z Med J; 2004 Oct; 117(1204):U1130. PubMed ID: 15505673 [No Abstract] [Full Text] [Related]
6. Avoiding another Vioxx. Beardsley S Sci Am; 2005 Feb; 292(2):16, 18. PubMed ID: 15715381 [No Abstract] [Full Text] [Related]
7. The Vioxx debacle. Alpert JS Am J Med; 2005 Mar; 118(3):203-4. PubMed ID: 15745713 [No Abstract] [Full Text] [Related]
8. Discontinuation of Vioxx. Garattini S; Bertelé V Lancet; 2005 Jan 1-7; 365(9453):24. PubMed ID: 15639671 [No Abstract] [Full Text] [Related]
9. The Vioxx debacle revisited. Manthous CA Am J Med; 2005 Sep; 118(9):1056-7; author reply 1057. PubMed ID: 16164904 [No Abstract] [Full Text] [Related]
10. The Vioxx debacle revisited. Mohapatra PR; Janmeja AK Am J Med; 2005 Sep; 118(9):1058. PubMed ID: 16164909 [No Abstract] [Full Text] [Related]
11. Vioxx, the implosion of Merck, and aftershocks at the FDA. Horton R Lancet; 2004 Dec 4-10; 364(9450):1995-6. PubMed ID: 15582041 [No Abstract] [Full Text] [Related]
12. How to avoid future Vioxx-type scandals. Prescrire Int; 2005 Jun; 14(77):115-7. PubMed ID: 15984108 [TBL] [Abstract][Full Text] [Related]
13. The vexations of Vioxx. Sibbald B CMAJ; 2006 Feb; 174(4):444-5. PubMed ID: 16477046 [No Abstract] [Full Text] [Related]
14. Discontinuation of Vioxx. Kim PS; Reicin AS Lancet; 2005 Jan 1-7; 365(9453):23; author reply 26-7. PubMed ID: 15639669 [No Abstract] [Full Text] [Related]
15. The story of Vioxx--no pain and a lot of gain: ethical concerns regarding conduct of the pharmaceutical industry. Cahana A; Mauron A J Anesth; 2006; 20(4):348-51. PubMed ID: 17072707 [No Abstract] [Full Text] [Related]
16. Vioxx should be allowed back on the market advises expert panel. Sibbald B CMAJ; 2006 Aug; 175(3):234. PubMed ID: 16880435 [No Abstract] [Full Text] [Related]
17. Health Canada lukewarm on Vioxx panel findings. Murray S CMAJ; 2005 Aug; 173(4):350. PubMed ID: 16103502 [No Abstract] [Full Text] [Related]
18. The Vioxx pharmaceutical scandal: Peterson v Merke Sharpe & Dohme (Aust) Pty Ltd (2010) 184 FCR 1. Faunce T; Townsend R; McEwan A J Law Med; 2010 Sep; 18(1):38-49. PubMed ID: 20977160 [TBL] [Abstract][Full Text] [Related]
19. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data". Luepker RV Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016 [No Abstract] [Full Text] [Related]